Engineered Microorganisms for Scalable Substituted Tryptamine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of psychoactive compounds like psilocybin, naturally produced by fungi, is limited by the difficulty in culturing these organisms and scaling up their production.
Innovation Solution
Genetically modified microorganisms, such as microalgae and stramenopiles, are engineered to overexpress tryptophan synthase and encode substituted tryptamine biosynthetic pathway enzymes, allowing for the production of psilocybin and other substituted tryptamines in a controlled, scalable manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If fungi are used to produce substituted tryptamines naturally, then the production of psychoactive compounds like psilocybin is achieved, but the difficulty in culturing and scaling up production limits the process
Solution Approach 1:
The patent copies the biosynthetic pathway from fungi to microorganisms. Specifically, fungal enzymes (tryptophan decarboxylase, tryptamine 4-monooxygenase, 4-hydroxytryptamine kinase, N-methyltransferase) are expressed in heterologous microorganisms to replicate the psilocybin production pathway, enabling scalable production without cultivating the original fungi
Solution Approach 2:
The patent uses microorganisms as intermediaries to produce substituted tryptamines. Instead of directly culturing fungi, the invention employs microorganisms (bacteria, yeast, insect cells, mammalian cells) that can be easily cultured and scaled, serving as intermediary production systems that achieve the same biochemical transformation
2Reliability
If fungal cultures are used for psilocybin production, then natural production is achieved, but the process is limiting and not economical for large-scale production
Solution Approach 1:
The patent changes the biological system parameter from fungi to microorganisms. By transforming the production system from fungal cultures to easily culturable microorganisms with engineered biosynthetic pathways, the invention maintains natural production capability while dramatically improving scalability and economic viability for large-scale production
3Productivity
If microorganisms are engineered to overexpress tryptophan synthase and biosynthetic enzymes, then high-yield production of substituted tryptamines is achieved, but genetic modification complexity increases
Solution Approach 1:
The patent segments the biosynthetic pathway into discrete enzymatic steps, each catalyzed by a separate enzyme (tryptophan decarboxylase, tryptamine 4-monooxygenase, 4-hydroxytryptamine kinase, N-methyltransferase). This segmentation allows independent optimization and expression of each enzyme in the microorganism, facilitating high-yield production while managing genetic modification complexity through modular construction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables high-yield production of substituted tryptamines, overcoming the limitations of fungal cultivation and providing a more economical and efficient method for producing these compounds.
Implementation Method 1
microorganisms comprising an overexpressed tryptophan synthase
Implementation Method 2
nucleic acid molecule that encodes at least one substituted tryptamine biosynthetic pathway enzyme comprising a tryptophan decarboxylase, an indole-ethylamine methyltransferase, a tryptamine 4-monooxygenase, and a 4-hydroxytryptamine kinase
Data Source
AI summary
Provided herein are microorganisms for producing substituted tryptamines and cell cultures thereof, the microorganisms comprising at least one exogenous nucleic acid molecule that encodes at least one substituted tryptamine biosynthetic pathway enzyme.